Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 55Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Myelodysplastic Syndromes 42Leukemia, Lymphocytic, Chronic, B-Cell 40Leukemia 38Lymphoma, Non-Hodgkin 32Multiple Myeloma 31Lymphoma 31Lymphoma, Mantle-Cell 26Lymphoma, Follicular 24Lymphoma, Large B-Cell, Diffuse 23Hodgkin Disease 22Melanoma 21Burkitt Lymphoma 19Lymphoma, B-Cell, Marginal Zone 18Leukemia, Myelomonocytic, Chronic 17Recurrence 14Anemia, Refractory, with Excess of Blasts 14Congenital Abnormalities 13Neoplasms, Plasma Cell 12Myeloproliferative Disorders 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large-Cell, Immunoblastic 11Hematologic Neoplasms 11Leukemia, Myeloid, Chronic-Phase 10Primary Myelofibrosis 9Lymphoma, Large-Cell, Anaplastic 9Lymphoma, B-Cell 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Ovarian Neoplasms 8

Interventions

Brentuximab Vedotin 7dacetuzumab 4Lenalidomide 3Doxorubicin 3Dexamethasone 3spartalizumab 2lintuzumab 2fludarabine 2Vincristine 2Rituximab 2Rifampin 2Prednisone 2Gemcitabine 2Cyclophosphamide 2tanespimycin 1sabatolimab 1pomalidomide 1pirtobrutinib 1fludarabine phosphate 1ficlatuzumab 1daratumumab 1Vinblastine 1Thiotepa 1TAS4464 1Sertraline 1R-CHOP protocol 1Pam2CSK4 acetate and ODN M362 combination 1Midazolam 1Melphalan 1LCL161 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Diseases × fludarabine phosphate × Clear all
NCT05755854 2023-09-22

Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors

Anhui Provincial Hospital

Phase 1 Unknown
10 enrolled

Hematologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡